How type I interferon affects treatment response in rheumatoid arthritis
Type I interferon Impacts Treatment Response in Rheumatoid Arthritis
This study is looking at how a substance called type I interferon affects how well people with rheumatoid arthritis respond to certain treatments, so we can find better ways to personalize their care and improve their outcomes.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hospital for Special Surgery NIH-funded |
| Lab location | 1 site (New York, UNITED STATES) |
| Project ID | NIH-10876931 on NIH RePORTER |
What this research studies
This research investigates the role of type I interferon in determining how well patients with rheumatoid arthritis respond to treatment, particularly tumor necrosis factor inhibitors. By analyzing blood samples from patients, the study aims to identify specific biomarkers that can predict treatment outcomes, which could lead to more personalized and effective therapies. The researchers will examine the relationship between circulating interferon levels and the activity of immune cells in the body, providing insights into the underlying mechanisms of treatment response. This approach may help clinicians choose the best treatment options for individual patients based on their unique biological profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with rheumatoid arthritis who are considering treatment with tumor necrosis factor inhibitors.
Not a fit: Patients who do not have rheumatoid arthritis or those who are not candidates for tumor necrosis factor inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment strategies for patients with rheumatoid arthritis.
How similar studies have performed: Previous research has shown promising results in using biomarkers to predict treatment responses in rheumatoid arthritis, suggesting that this approach may be effective.
Where this research is happening
New York, UNITED STATES
- Hospital for Special Surgery — New York, United States (Active)
Researchers
- Principal investigator: Wampler Muskardin, Theresa — Hospital for Special Surgery
- Study coordinator: Wampler Muskardin, Theresa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.